Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20932792 | 0.91 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL19115263 | 0.87 | — | — | |
| SCHEMBL18519236 | 0.87 | MEN1 (0.61) | ALDH1A1MEN1KMT2AUSP2CYP1A2 | |
| SCHEMBL16844919 | 0.87 | KDM4E (0.50) | ALDH1A1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL18510181 | 0.87 | KDM4E (0.50) | ALDH1A1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL1927840 | 0.85 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL1927654 | 0.85 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL15947374 | 0.85 | — | — | |
| SCHEMBL3921384 | 0.83 | — | — | |
| SCHEMBL10050997 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 973 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689130-A2 | METHODS AND COMPOSITIONS FOR ENHANCED EXPRESSION OF EXOGENOUS CASEINS IN TRANSGENIC PLANTS | Mozza Foods Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250195567-A1 | COMPOSITIONS FOR REMOVING MICROBIAL BIOFILM OR INHIBITING FORMATION THEREOF | PRUDENTIX LTD. (IL) | 2025-06-19 | — | — | US | claimed |
| EP-4493283-A1 | COMPOSITIONS FOR REMOVING MICROBIAL BIOFILM OR INHIBITING FORMATION THEREOF | Prudentix Ltd. (IL) | 2025-01-22 | — | — | EP | claimed |
| WO-2024206469-A2 | METHODS AND COMPOSITIONS FOR ENHANCED EXPRESSION OF EXOGENOUS CASEINS IN TRANSGENIC PLANTS | Mozza Foods Inc. (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2023175603-A1 | COMPOSITIONS FOR REMOVING MICROBIAL BIOFILM OR INHIBITING FORMATION THEREOF | PRUDENTIX LTD. (IL) | 2023-09-21 | — | — | WO | claimed |
| WO-2018158763-A1 | PERIODONTAL COMPOSITION AND METHOD OF USE | PRUDENTIX LTD. (IL) | 2018-09-07 | — | — | WO | claimed |
| EP-0388220-B1 | Compositions for the sustained release of chlorhexidine | YISSUM RES DEV CO (IL) | 1995-03-08 | — | — | EP | claimed |
| EP-0246809-B1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1992-09-30 | — | — | EP | claimed |
| US-5002769-A | Periodontristry, Plasticizer, Crosslinked Water Insoluble Protein Matrix | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1991-03-26 | — | — | US | claimed |
| WO-1987007140-A1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (US) | 1987-12-03 | — | — | WO | claimed |
| EP-0092908-A2 | Hydrophilic polymer composition for injection molding | WARNER-LAMBERT COMPANY (US) | 1983-11-02 | — | — | EP | claimed |
| EP-4746899-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH TROP-2 TARGETING ADC | Iovance Biotherapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12629612-B2 | Material and method for performing a separation based on halogen bonding | MERCK PATENT GMBH (DE) | 2026-05-19 | — | — | US | disclosed |
| WO-2026102333-A1 | METHODS OF TREATING CARDIOMYOPATHY USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-4350626-A | COUPLED FRAGMENTS OF IMMUNOGLOBULIN AND RICIN | TEIJIN LIMITED (JP) | 1982-09-21 | — | — | US | disclosed |
| EP-0023779-A1 | Antitumor protein hybrid and process for the preparation thereof | TEIJIN LIMITED (JP) | 1981-02-11 | — | — | EP | disclosed |
| EP-0023401-A2 | Antitumor protein hybrid and process for the preparation thereof | TEIJIN LIMITED (JP) | 1981-02-04 | — | — | EP | disclosed |
| EP-0017507-A2 | Antitumor protein hybrid and process for the preparation thereof | TEIJIN LIMITED (JP) | 1980-10-15 | — | — | EP | disclosed |
| US-4147767-A | CROSSLINKED WITH FORMALDEHYDE OR GLUTARALDEHYDE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629612-B2 | Material and method for performing a separation based on halogen bonding | RCC1, CFH, CTCF | ALDH1A1 2475/4885SMN1; SMN2 4392/4885MEN1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.